Rennes

• Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Ca … Recruiting
  2022-502352-31-00 5 2025-02-10 Colorectal Cancer (CRC)
• Multicentric Phase 1 Study With Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine) or CPX-351 … Recruiting
  2022-502585-25-00 3 2025-02-06 Adult patients with adverse Risk Acute Myeloblastic Leukemia
• PRODIGE 90 - FFCD 22024 - PREDIR-NEOREC - Neoadjuvant dostarlimab with short course radiotherapy in a watch-and-wait strategy for microsatel … Recruiting
  2024-510772-20-00 4 2025-02-06 Rectal cancer locally advanced with microsatellite unstable or mismatc
• DISEASE MODIFYING THERAPIES WITHDRAWAL IN INACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS AGED 55 AND OVER: A MULTICENTRIC, RANDOMI … Recruiting
  2024-513475-41-00 5 2025-02-03 Multiple Sclerosis
• A study describing the efficacy and safety of belimumab administered subcutaneously in adult participants with early systemic lupus erythema … Recruiting
  2023-509146-35-00 6 2025-01-30 Systemic Lupus Erythematosus
• SUPPRESS. Prophylactic frequent premature ventricular complexeS sUPPression on left ventriculaR function impairmEnt in aSymptomatic patientS Recruiting
  2024-516372-14-00 11 2025-01-13 Asymptomatic Patients with frequent PVCs and normal LVEF
• Phase I/II randomized clinical trial of allogeneic adipose tissue-derived mesenchymal stromal cells systemic infusion in severe systemic scl … Recruiting
  2023-505977-34-00 4 2025-01-08 Systemic sclerosis
• EvER-ILD 3 : Evaluation of Efficacy and safety of Rituximab and mycophenolate mofetil combination in patients with Interstitial Lung Disease … Recruiting
  2023-510507-21-00 10 2025-01-08 Intersitial lung disease related to systemic sclerosis
• Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-resistant Patients Scheduled to Undergo … Recruiting
  2023-507560-39-00 5 2025-01-07 Acquired Antithrombin Deficiency (Heparin Resistance)
• Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma Recruiting
  2024-511188-26-00 5 2024-12-20 Relapsed/refractory multiple myeloma in patients who have received 1 t
• A study to determine if BHV-7000 is safe in adults with refractory focal onset epilepsy Recruiting
  2023-508813-18-00 4 2024-12-18 Refractory Focal Onset Epilepsy
• A Phase 3 efficacy and safety study of fosmanogepix for the treatment of adult participants with candidemia and/or invasive candidiasis. Recruiting
  2022-500455-23-00 5 2024-12-11 Candidemia
• A clinical trial to learn about the effects of YTB in people with difficult to treat active systemic lupus erythematosus (SLE), or active k … Recruiting
  2023-510150-17-00 4 2024-12-11 Active, refractory systemic lupus erythematosus (SLE), and active, re
• A clinical trial to learn about the effects of YTB323 in people with difficult to treat severe diffuse cutaneous systemic sclerosis (dcSSc) Recruiting
  2023-510380-34-00 4 2024-12-10 Diffuse cutaneous systemic sclerosis (dcSSc)
• Short versus long antiplatelet therapy after TAVI Recruiting
  2023-508208-40-00 10 2024-11-21 All adult patients with successful transfemoral trans-aortic valve imp
• Multicentre randomised double-blind superiority trial with a roll-over phase to evaluate the efficacy of OM-89 vs placebo in reducing antibi … Recruiting
  2024-512595-35-00 5 2024-11-21 neurogenic bladder
• Study of Targeted Therapies for the Treatment of Adult Participants with Moderate to Severe Crohn’s Disease Recruiting
  2024-513009-30-00 4 2024-11-21 Moderate to Severe Crohn’s Disease
• HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN: Randomised, international and multicentric phase 3 study t … Recruiting
  2024-514917-36-00 5 2024-11-21 Patients with High Risk Neuroblastoma
• A study to test if different doses of D3S-001 used on its own or in combination with other anti-cancer medicines is safe and tolerable in pe … Recruiting
  2023-508517-16-00 7 2024-11-10 Advanced Solid Tumors with a KRAS p.G12C Mutation
• Comparison of a personalized maintenance therapy based on the evolution of anti-desmoglein antibodies as biomarkers of pemphigus subclinical … Recruiting
  2024-514886-21-00 6 2024-11-06 Pemphigus diseases (Pemphigus Vulgaris - PV and Pemphigus Foliaceus (P
• A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Can … Recruiting
  2023-509340-10-00 5 2024-10-29 Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell
• A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy Recruiting
  2023-508539-30-00 4 2024-10-10 Refractory Focal Onset Epilepsy
• OPEN-LABEL PHASE II EFFICACY STUDY OF REPOTRECTINIB IN FRAIL (PS ≥2) AND /OR ELDERLYPATIENTS WITH ROS1-REARRANGED ADVANCED NSCLC Recruiting
  2023-509073-23-00 4 2024-10-01 Stage III/IV non-small-cell lung cancer (NSCLC) harboring an ROS1 gene
• A Placebo-Controlled Study of Inhaled Pirfenidone in Progressive Pulmonary Fibrosis Recruiting
  2023-508429-29-00 4 2024-09-26 Progressive Pulmonary Fibrosis

Showing 169–192 of 519 trials